- Ertugliflozin plus sitagliptin is more effective than either treatment alone for the reduction of HbA1c and fasting plasma glucose (FPG).
Why this matters
- Ertugliflozin is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor in development for the treatment of type...
You’ve reached the visitor articles limit
reserved for healthcare professionals
Register to read more
Already have an account? Login now